Table 5.
Study Characteristics and Results for Hokusai Cancer VTE, SELECT-D, and Caravaggio Studies for VTE Treatment
| Hokusai Cancer VTE | SELECT-D | Caravaggio | |
|---|---|---|---|
| Population | 1,046 patients with cancer and acute symptomatic or incidentally detected VTE | 406 patients with cancer and acute symptomatic or incidentally detected VTE | 1,155 patients with cancer and a diagnosis of symptomatic or incidental acute proximal DVT or PE |
| Duration, months | 12 | 6 | 6 |
| Treatment Arms | Edoxaban | Dalteparin | Rivaroxaban | Dalteparin | Apixaban | Dalteparin |
|---|---|---|---|---|---|---|
| Metastatic disease, % | 52.5 | 53.4 | 58 | 58 | 67.5 | 68.4 |
| Concurrent anticancer treatment, % | 71.6 | 73.1 | 69 | 70 | 60.8. | 63.4 |
| Recurrent VTE, % | 7.9 | 11.3 | 4 | 11 | 5.6 | 7.9 |
| HR (95% CI); p value | 0.71 (0.48–1.06); p = 0.09 | 0.43 (0.19–0.99); p = NR | 0.63 (0.37–1.07); p < 0.001 | |||
| Major bleeding, % | 6.9 | 4.0 | 6 | 4 | 3.8 | 4.0 |
| HR (95% CI); p value | 1.77 (1.03–3.04); p = 0.04 | 1.83 (0.68–4.96); p = NR | 0.82 (0.40–1.69); p = 0.60 | |||
| CRNMB, % | 14.6 | 11.1 | 13 | 4 | 9.0 | 6.0 |
| HR (95% CI); p value | 1.38 (0.98–1.94); p = NR | 3.76 (1.63–8.69); p = NR | 1.42 (0.88–2.30); p = NR | |||
| Mortality, % | 39.5 | 36.6 | 25 | 30 | 23.4 | 26.4 |
| HR (95% CI); p value | 1.12 (0.92–1.37); p = NR | NR | 0.82 (0.62–1.09); p = NR | |||
SELECT-D = Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism; other abbreviations as in Table 4.